Amundi MSCI Pacific Ex Japan UCITS ETF Dist
PAXJ.L
London Stock Exchange- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management - Global
- Address
- 5 Allée Scheffer Luxembourg City Luxembourg L-2520
- IPO Date
- Apr 29, 2015
- Website
- amundietf.nl
- Similar Companies
- Business
- Multi Units Luxembourg SICAV - Amundi MSCI Pacific Ex Japan UCITS ETF Dist (PAXJ.L) is a UCITS-compliant exchange-traded fund that seeks to track the performance of the MSCI Pacific ex Japan Net Total Return USD Index through full physical replication; it invests primarily in large- and mid-cap equities from developed Pacific markets excluding Japan, including significant exposure to Australian, Hong Kong, Singaporean, and New Zealand securities; the fund distributes dividends annually and features a total expense ratio of 0.12%. Launched on April 29, 2015, and domiciled in Luxembourg, the ETF manages approximately EUR 240 million in assets under management and trades on exchanges such as the London Stock Exchange, with listings available in France, Germany, Switzerland, and the United Kingdom. Managed by Amundi Asset Management SAS, it targets institutional and retail investors seeking diversified exposure to the Pacific ex-Japan equity region without currency hedging. In November 2025, Amundi, the fund's provider, announced a long-term strategic partnership and equity alliance with Intermediate Capital Group (ICG), under which Amundi will acquire a 9.9% economic stake in ICG2 to enhance its private markets offerings, including the planned launch of European evergreen private equity secondaries and private debt funds targeted at wealth investors in the first half of 2026; this move supports Amundi's ambitions to expand in high-growth asset classes amid its ongoing integration of prior acquisitions like Lyxor.